Drug-Drug Interactions in Recently Approved Antibacterials: A Mini Review
Abstract
Drug-drug interactions (DDIs) pose an important concern in elderly and multimorbid patients receiving complex pharmacotherapy. The addition of antimicrobial therapy can increase DDI risk, potentially reducing therapeutic efficacy or increasing toxicity. This review evaluates pharmacokinetic DDIs associated with antibacterial agents approved between 2012 and 2024 in the European Union (EU) and UK. To this end, all studies published on recently introduced antibiotics were consulted, with a focus on cytochrome P450 (CYP450) modulation, renal transporter interactions, and their clinical implications, excluding the papers concerning pharmacodynamics and spectrum of action. A systematic search of the PubMed database and summary of product characteristics (SmPCs) was conducted using key terms such as "drug-drug interaction," "DDI," "antibiotic," and "CYP450," combined with the name of the respective antibacterial agent. Human data were prioritized, although in vitro studies were included when clinical data were unavailable. Among the evaluated agents, cefiderocol, oritavancin, and meropenem/vaborbactam showed capacity for CYP450-mediated interactions. Although most examined antibiotics carry minimal risk of CYP-mediated DDIs, interactions with renal transporters may still pose clinical concerns, particularly when coadministered with nephrotoxic drugs. In conclusion, most recently approved antibiotics have a low potential for interaction, but certain agents may carry clinically…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.